New Insights into Therapy-Induced Progression of Cancer

The malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. Howeve...

Full description

Bibliographic Details
Main Authors: Polina V. Shnaider, Olga M. Ivanova, Irina K. Malyants, Ksenia S. Anufrieva, Ilya A. Semenov, Marat S. Pavlyukov, Maria A. Lagarkova, Vadim M. Govorun, Victoria O. Shender
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/21/7872
_version_ 1797549990057345024
author Polina V. Shnaider
Olga M. Ivanova
Irina K. Malyants
Ksenia S. Anufrieva
Ilya A. Semenov
Marat S. Pavlyukov
Maria A. Lagarkova
Vadim M. Govorun
Victoria O. Shender
author_facet Polina V. Shnaider
Olga M. Ivanova
Irina K. Malyants
Ksenia S. Anufrieva
Ilya A. Semenov
Marat S. Pavlyukov
Maria A. Lagarkova
Vadim M. Govorun
Victoria O. Shender
author_sort Polina V. Shnaider
collection DOAJ
description The malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. However, remaining cancer cells may rapidly reestablish the tumor after a temporary remission. These new populations of malignant cells usually have increased resistance not only to the first-line agent, but also to the second- and third-line drugs, leading to a significant decrease in patient survival. Multiple studies describe the mechanism of acquired therapy resistance. In past decades, it became clear that, in addition to the simple selection of pre-existing resistant clones, therapy induces a highly complicated and tightly regulated molecular response that allows tumors to adapt to current and even subsequent therapeutic interventions. This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy. Moreover, we describe less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Understanding these molecular mechanisms will be beneficial in finding novel therapeutic approaches for cancer therapy.
first_indexed 2024-03-10T15:23:00Z
format Article
id doaj.art-c4995a1ba51e4881bfe1b0af893699f1
institution Directory Open Access Journal
issn 1661-6596
1422-0067
language English
last_indexed 2024-03-10T15:23:00Z
publishDate 2020-10-01
publisher MDPI AG
record_format Article
series International Journal of Molecular Sciences
spelling doaj.art-c4995a1ba51e4881bfe1b0af893699f12023-11-20T18:20:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-012121787210.3390/ijms21217872New Insights into Therapy-Induced Progression of CancerPolina V. Shnaider0Olga M. Ivanova1Irina K. Malyants2Ksenia S. Anufrieva3Ilya A. Semenov4Marat S. Pavlyukov5Maria A. Lagarkova6Vadim M. Govorun7Victoria O. Shender8Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Cell Biology, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Cell Biology, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaLaboratory of Membrane Bioenergetics, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaLaboratory of Simple Systems, Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, RussiaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, RussiaThe malignant tumor is a complex heterogeneous set of cells functioning in a no less heterogeneous microenvironment. Like any dynamic system, cancerous tumors evolve and undergo changes in response to external influences, including therapy. Initially, most tumors are susceptible to treatment. However, remaining cancer cells may rapidly reestablish the tumor after a temporary remission. These new populations of malignant cells usually have increased resistance not only to the first-line agent, but also to the second- and third-line drugs, leading to a significant decrease in patient survival. Multiple studies describe the mechanism of acquired therapy resistance. In past decades, it became clear that, in addition to the simple selection of pre-existing resistant clones, therapy induces a highly complicated and tightly regulated molecular response that allows tumors to adapt to current and even subsequent therapeutic interventions. This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy. Moreover, we describe less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Understanding these molecular mechanisms will be beneficial in finding novel therapeutic approaches for cancer therapy.https://www.mdpi.com/1422-0067/21/21/7872cancer progressionchemotherapychemoresistancetumor microenvironmentintercellular communicationcell cycle
spellingShingle Polina V. Shnaider
Olga M. Ivanova
Irina K. Malyants
Ksenia S. Anufrieva
Ilya A. Semenov
Marat S. Pavlyukov
Maria A. Lagarkova
Vadim M. Govorun
Victoria O. Shender
New Insights into Therapy-Induced Progression of Cancer
International Journal of Molecular Sciences
cancer progression
chemotherapy
chemoresistance
tumor microenvironment
intercellular communication
cell cycle
title New Insights into Therapy-Induced Progression of Cancer
title_full New Insights into Therapy-Induced Progression of Cancer
title_fullStr New Insights into Therapy-Induced Progression of Cancer
title_full_unstemmed New Insights into Therapy-Induced Progression of Cancer
title_short New Insights into Therapy-Induced Progression of Cancer
title_sort new insights into therapy induced progression of cancer
topic cancer progression
chemotherapy
chemoresistance
tumor microenvironment
intercellular communication
cell cycle
url https://www.mdpi.com/1422-0067/21/21/7872
work_keys_str_mv AT polinavshnaider newinsightsintotherapyinducedprogressionofcancer
AT olgamivanova newinsightsintotherapyinducedprogressionofcancer
AT irinakmalyants newinsightsintotherapyinducedprogressionofcancer
AT kseniasanufrieva newinsightsintotherapyinducedprogressionofcancer
AT ilyaasemenov newinsightsintotherapyinducedprogressionofcancer
AT maratspavlyukov newinsightsintotherapyinducedprogressionofcancer
AT mariaalagarkova newinsightsintotherapyinducedprogressionofcancer
AT vadimmgovorun newinsightsintotherapyinducedprogressionofcancer
AT victoriaoshender newinsightsintotherapyinducedprogressionofcancer